Alector, Inc.
10-K
February 25, 2026
Key Highlights
- Alector is a clinical-stage biotechnology company pioneering immuno-neurology fo...
- Achieved significant clinical progress, including completing AL001 Phase 2 (FTD)...
- Reported $75.2 million in collaboration revenue for 2023, a 15% increase, primar...
Read Analysis
🤖 AI Generated